Non-vitamin K antagonist oral anticoagulants (NOACs) should be the preferred
anticoagulant strategy for preventing ischemic stroke in patients with atrial fibrillation (AF) at …

Non-vitamin K oral anticoagulants (NOACs) have revolutionized anticoagulant therapy,
offering improved safety and efficacy over traditional agents like warfarin. This review …

The use of non-vitamin K antagonist oral anticoagulants (NOACs) has brought a significant
progress in the management of cardiovascular diseases, considered clinically superior to …

The frequent coexistence in daily clinical practice of chronic kidney disease (CKD) and atrial
fibrillation (AF), especially in the elderly, represents a conundrum for physicians, mainly …

Background In atrial fibrillation (AF) patients on vitamin K antagonists, a progressive
deterioration of renal function is common but there is limited evidence with long‐term use of …

Background The use of anticoagulants is an established strategy to prevent stroke,
embolism, and cardiovascular mortality in patients with atrial fibrillation (AF), but its role in …

Calcific aortic stenosis (CAS) is currently recognized as the third most frequent
cardiovascular disorder in persons aged above 60 years, after atherosclerotic disease and …

Abstract Background Direct oral anticoagulants (DOACs) have emerged as the first-line
therapy for venous thromboembolism and stroke prophylaxis in atrial fibrillation. As DOACs …

Aims We aim to explore the correlation between coronary artery calcification (CAC) score
(CACS) and cardiac structure and function in chronic kidney disease (CKD) patients, create …

Rivaroxaban is a direct, oral factor Xa inhibitor that is used for the prevention and treatment
of various thromboembolic disorders. Several preclinical and clinical studies have utilized …